Verma S, et al. - Because cardiovascular risk reduction for liraglutide and semaglutide was demonstrated in LEADER and SUSTAIN 6 cardiovascular outcome trials in patients with type 2 diabetes, researchers used a Cox proportional hazards model to evaluate the impact of diabetes duration (<5, 5 to <15, 15 to <25 and ≥25 years at baseline) on cardiorenal efficacy of these human glucagon-like peptide-1 analogues. Major adverse cardiovascular events (MACE) increased frequency, expanded MACE and nephropathy events with an increased duration of diabetes. According to this post hoc analysis, the risk of cardiorenal outcomes across diabetes duration categories was consistently reduced by liraglutide and semaglutide.